GN Store Nord A/S – Notice to convene the Annual General Meeting 2026




GN Store Nord A/S – Notice to convene the Annual General Meeting 2026

GN Store Nord’s Annual General Meeting will be held on Wednesday, March 11, 2026, at 10:00 a.m. CET at the company’s address: Lautrupbjerg 7, 2750 Ballerup, Denmark.

Please find attached the notice to convene the Annual General Meeting, including the agenda and complete proposals.

For further information, please contact:

Investor Relations
Rune Sandager +45 45 75 92 57

Media Relations
Steen Frentz Laursen +45 20 65 34 20

About GN
GN facilitates communication between people through intelligent hearing, audio, video, and gaming technology. Inspired by people and driven by our passion for innovation, we leverage technologies to deliver unique user experiences that bring people closer through the power of sound and vision.

GN was founded more than 150 years ago with a vision to connect the world. Today, we proudly honor that legacy with our world-leading expertise in the human ear, audio, video and speech, wireless technologies, software, miniaturization, and collaboration with leading technology partners. GN’s solutions are marketed by the brands ReSound, SteelSeries, Jabra, Beltone, Interton, BlueParrott, Danavox and FalCom in 100 countries. Founded in 1869, the GN Group employs 7,000 people and is listed on Nasdaq Copenhagen (GN.CO).

Visit our homepage GN.com – and connect with us on LinkedIn, Facebook and X.

Attachment

• Notice of Annual General Meeting 2026

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board




Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in Huntington’s disease

Clinical Advisory Board formed to support progression of HRN001 into first-in-human studies in 2027

Dr Andy Billinton, CSO will present preclinical data at the upcoming CHDI Foundation Huntington’s Disease Therapeutics Conference

Cambridge, UK, 16 February 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces the nomination of HRN001 as its lead drug candidate for Huntington’s disease and the formation of a clinical advisory board to support the programme’s advancement towards clinical evaluation.

Huntington’s disease (HD) is a devastating, inherited neurodegenerative disorder that leads to progressive cognitive, psychiatric and motor decline, with death often occurring within 15 years of symptom onset. Despite significant advances in understanding HD disease biology, there are currently no approved disease-modifying treatments available.

HD is caused by the expansion of CAG repeats in the huntingtin (HTT) gene. Ongoing somatic expansion of these repeats is now recognised as a key driver of disease onset and progression. FAN1 nuclease has emerged as one of the most compelling targets to suppress somatic expansion, demonstrating the strongest genetic association to disease onset in genome-wide association studies.

Our first-in-class candidate HRN001 is a potent and specific antisense oligonucleotide targeting FAN1, designed to drive controlled upregulation of this key DNA repair nuclease. It leverages Harness’ proprietary MISBA® (microRNA site blocking ASO) platform, which enables precise upregulation of target protein levels without risk of over-expression.

HRN001 has demonstrated robust upregulation of FAN1 and slowing of somatic expansion in models of HD, as well as favourable PK and tolerability characteristics. Preclinical development will continue throughout 2026 to support clinical entry in 2027. Harness is exploring the potential of the MISBA® platform in other triplet repeat disorders and across a broader pipeline of neurodegenerative disorders.

To support the progression of HRN001 towards the clinic, Harness has established a clinical advisory board (CAB) comprising leading experts in the HD field, including:

Dr. Irina Antonijevic (Chair) – Chief Medical Officer, Trace Neuroscience
Dr. Anne Rosser – Professor of Clinical Neuroscience, Cardiff University
Dr. Jeffrey Long – Professor of Psychiatry and Biostatistics, University of Iowa Health Care
Dr. Ralf Reilmann – Founding Director and Chief Executive Officer, George-Huntington-Institute
Dr. Roger Barker – Professor of Clinical Neuroscience, University of Cambridge
Dr. Sarah Tabrizi – Professor of Clinical Neurology, University College London
Dr. William Gray – Professor of Functional Neurosurgery, Cardiff University

The CAB will provide strategic guidance on clinical development, trial design, and translational strategy as the programme advances towards the clinic.

Dr Andy Billinton, Chief Scientific Officer of Harness Therapeutics, will present the company’s work in HD at the upcoming annual CHDI Huntington’s Disease Therapeutics Conference in Palm Springs, California, 23^rd-26^th February, providing further insights into the scientific rationale and development progress for HRN001.

Dr Jan Thirkettle, CEO of Harness Therapeutics, commented: “The nomination of HRN001 represents a pivotal milestone for Harness and underscores our commitment to the Huntington’s disease community. By precisely upregulating FAN1, a target with compelling genetic validation in delaying disease onset, HRN001 represents a differentiated, first-in-class therapeutic approach for addressing somatic expansion, a fundamental driver of disease progression. The formation of a Clinical Advisory Board brings deep clinical and translational expertise to the programme. The CAB will work closely with Harness as we advance HRN001 towards the clinic and seek to deliver a truly disease-modifying therapy for patients and families living with Huntington’s disease.”

Dr Irina Antonijevic, Chair of Harness Therapeutics’ Clinical Advisory Board, added: “FAN1 is one of the most compelling and consistently validated genetic modifiers of Huntington’s disease identified to date, with a clear mechanistic link to somatic expansion and disease progression. Harness’ approach with HRN001 offers a novel and highly targeted way to therapeutically modulate this pathway. We look forward to advising the Company, as it advances HRN001 toward the clinic, translating this promising science into a clinical programme that could meaningfully alter the course of this devasting disease.”

CHDI presentation details
Title: Upregulation of FAN1 with ASOs as a potential therapeutic strategy for triplet repeat disorders
Session: Somatic Instability/Mismatch Repair
Date: Tuesday 24 February
Presenter: Dr Andy Billinton, CSO of Harness Therapeutics

CAB biographies

Dr. Irina Antonijevic (Chair) is an experienced clinician and drug development leader, widely recognized for her leadership in advancing innovative therapies from early development through clinical stages, particularly in areas with high unmet medical needs such as neurodegenerative and psychiatric disorders. She currently serves as Chief Medical Officer at Trace Neuroscience, bringing over three decades of experience in clinical psychiatry, neurology, academic research, and therapeutic drug development. Dr. Antonijevic is a board-certified physician trained in both psychiatry and neurology, with deep expertise in translational medicine and clinical development strategies.

Dr. Anne Rosser is Professor of Clinical Neuroscience at Cardiff University and an Honorary Consultant Neurologist at the University Hospital of Wales, leading the South Wales clinical service for Huntington’s disease. She co-leads the Cardiff University Brain Repair Group, a multidisciplinary research team focused on developing cell-based and regenerative therapies for neurodegenerative diseases. Dr. Rosser previously served as Chair of the European Huntington’s Disease Network (EHDN) and is currently Chair of the Scientific Committee of the Lister Institute of Preventive Medicine.

Dr. Jeffrey D. Long is Professor of Psychiatry and Biostatistics at the University of Iowa Health Care / Carver College of Medicine where he applies statistical modeling to neurodegenerative diseases, with a special emphasis on Huntington’s disease. He develops and refines disease progression indexes, critical for understanding natural disease trajectories and planning clinical trials. Dr Long also serves as Lead Biostatistician for NIH-funded longitudinal studies, such as REDICT-HD, and plays a key role as Head Biostatistician in the Data Coordinating Center of the NeuroNEXT clinical trials network.

Dr. Ralf Reilmann is Founding Director and Chief Executive Officer of the George-Huntington-Institute (GHI) in Münster, Germany, a private research institute devoted to clinical care and research in Huntington’s disease. Under his leadership, the Institute participates in key Huntington’s observational studies including ENROLL-HD and clinical trials exploring disease-modifying therapies and gene therapy approaches. Dr. Reilmann is a board-certified neurologist, widely recognized for his commitment to improving trial outcomes, patient care, and global collaboration in Huntington’s research.

Dr. Roger Barker Professor of Clinical Neuroscience at the University of Cambridge and Honorary Consultant Neurologist at Addenbrooke’s Hospital, Cambridge. He serves as Lead Academic Scientist for the Alzheimer’s Research UK Drug Discovery Institute in Cambridge and Lead Consultant for the East of England Huntington’s Disease Service. His research focuses on clinical characterization of neurodegenerative disorders and the development of new therapeutic approaches, especially cell- and gene-based treatments. Dr. Barker has led and coordinated major research programmes, including European projects and stem cell trials for Parkinson’s disease as well as a range of trials in Huntington’s disease.

Dr. Sarah Tabrizi is Professor of Clinical Neurology at University College London, internationally recognised for her research in neurodegenerative diseases, particularly Huntington’s disease. She holds several prestigious roles across UCL’s neuroscience community and the UK’s top clinical research institutions recognised with many major awards. Her work has transformed the Huntington’s field, establishing frameworks for disease staging, biomarker development, and therapeutic trials that serve as models for other neurodegenerative conditions. Dr. Tabrizi’s bench-to-bedside approach integrates deep biological insight with clinical trials to bring hope to patients with previously untreatable conditions.

Dr. William Gray is Professor of Functional Neurosurgery at Cardiff University and Honorary Consultant Neurosurgeon at the University Hospital of Wales. He brings dual expertise in clinical neurosurgery and neuroscience research, especially focused on disorders like epilepsy, Parkinson’s disease, Huntington’s disease, and frontotemporal dementia. He serves as Director of the Advanced NeuroTherapies Centre (ANTC), developing and delivering emerging therapies directly to the brain, is the Academic Lead in Neurosurgery in Wales, and Head of the Brain Repair and Intracranial Neurotherapeutics (BRAIN) Unit. Dr. Gray is the UK Chief Investigator for the uniQure AMT-130 gene therapy trial in Huntington’s disease and Principal Investigator for gene therapy trials in frontotemporal dementia and Parkinson’s disease. He also co-leads the European Huntington’s Disease Network ATMP Working Group and chairs its Surgical Delivery Task Force.

-ENDS-

About Harness Therapeutics 
Harness Therapeutics is a biotechnology company focused on unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases. Its MISBA® platform technology enables precise upregulation of target protein levels by modulating mechanisms controlling protein synthesis. Harness’ recently announced MISBA® Duo technology enables the design of single constructs which simultaneously upregulate one target whilst downregulating a second. Using its deep understanding of post-transcriptional regulation and sophisticated neuron-based models, Harness’ approach allows drugging of potentially disease-modifying targets, which would not be addressable using gene therapy or other modalities.

Its lead candidate in Huntington’s Disease, HRN001, targets FAN1 nuclease, a key protective protein, shown to slow disease progression. Its pipeline also includes programmes addressing compelling first in class targets for ALS, Alzheimer’s Disease, and Parkinson’s Disease.

Harness has assembled a world-class team, supported by leading experts in neurodegeneration and RNA biology, and is based in Cambridge, UK. Its leading life science investors include the foundational investors Takeda Ventures and SV Health Investors’ Dementia Discovery Fund, alongside Epidarex Capital and Ono Ventures Investment.

For more information, please visit https://www.harnesstx.com/ and follow us on LinkedIn.

For further information, please contact:        

ICR Healthcare
Amber Fennell, Stephanie Cuthbert,
Tel: +44 20 3709 5700
Email: harnesstx@icrinc.com

Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470




Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470

Attachment

• EN_NCX470PreNDAFebruary2026_FINAL

Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease




Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease

• MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years
• Up to 30% of people with membranous nephropathy progress to kidney failure over 10 years despite current treatment approaches; achieving complete remission can help delay or prevent this^1,2
• Gazyva/Gazyvaro could become the first approved treatment for primary membranous nephropathy, having already achieved positive results in lupus nephritis, systemic lupus erythematosus and idiopathic nephrotic syndrome
• Gazyva/Gazyvaro is a glycoengineered, anti-CD20 monoclonal antibody designed to achieve deep tissue B cell depletion

Basel, 16 February 2026 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistically significant and clinically meaningful results with Gazyva®/Gazyvaro® (obinutuzumab). Results show that significantly more people achieved complete remission at two years (104 weeks) with Gazyva/Gazyvaro versus tacrolimus. Safety was in line with the well-characterised profile of Gazyva/Gazyvaro and no new safety signals were identified.

“These results demonstrate that Gazyva/Gazyvaro may help more people with primary membranous nephropathy achieve complete remission, maintain kidney function for longer and delay or potentially prevent the onset of life-threatening complications,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “If approved, Gazyva/Gazyvaro would be the first therapy specifically indicated for people with primary membranous nephropathy, where there are limited treatment options.”

Analysis of key secondary endpoints showed statistically significant and clinically meaningful benefits with Gazyva/Gazyvaro versus tacrolimus in overall remission (complete or partial remission) at week 104 and complete remission at week 76.

Data will be presented at an upcoming medical meeting and shared with health authorities including the US Food and Drug Administration and the European Medicines Agency.

Primary membranous nephropathy is a chronic autoimmune condition that causes potentially irreversible kidney damage and reduced kidney function, and it is estimated that it affects  nearly 88,000 people in the EU and over 96,000 in the US. Up to 30% of people with primary membranous nephropathy will develop kidney failure over 10 years, which requires invasive intervention like dialysis or transplant and has a significant impact on patients and their families, as well as carrying substantial cost to health systems.^1,2 Gazyva/Gazyvaro has the potential to address this by targeting an underlying cause of the condition, which may help maintain kidney function for longer and prevent the onset of life-threatening complications.

MAJESTY is the fourth positive phase III study of Gazyva/Gazyvaro in immune-mediated diseases, following REGENCY in lupus nephritis, ALLEGORY in systemic lupus erythematosus and INShore in idiopathic nephrotic syndrome. This growing body of evidence supports Gazyva/Gazyvaro’s potential in addressing disease activity across a spectrum of immune-mediated diseases.

Gazyva/Gazyvaro is approved in the US and EU for the treatment of adults with active lupus nephritis based on data from the REGENCY and NOBILITY studies and is being investigated in a global phase II study of children and adolescents with lupus nephritis.^3,4 Beyond Gazyva/Gazyvaro, we have a broad pipeline as part of our ambition to be leaders in immunology, in particular in immune-mediated and kidney-related diseases.

About Gazyva/Gazyvaro
Gazyva®/Gazyvaro® (obinutuzumab) is a humanised monoclonal antibody designed with a Type II anti-CD20 region, for direct B cell death and a glycoengineered Fc region, for higher binding affinity and increased antibody-dependent cellular cytotoxicity (ADCC). CD20 is a protein found on certain types of B cells.

Gazyva/Gazyvaro is approved for adults with lupus nephritis in the US and EU. Gazyva/Gazyvaro is also approved in 100 countries for various types of haematological cancers.

About the MAJESTY study
MAJESTY [NCT04629248] is a phase III, randomised, open-label,  multicentre study designed to evaluate the efficacy and safety of Gazyva®/Gazyvaro® (obinutuzumab) in people with primary membranous nephropathy. The study enrolled 142 people who were randomised 1:1 to receive Gazyva/Gazyvaro or tacrolimus. The primary endpoint is the percentage of people who achieve complete remission at two years (week 104).

About primary membranous nephropathy
Primary membranous nephropathy is a chronic autoimmune condition where the body’s immune system attacks the filtering units of the kidney, the glomeruli, causing protein to leak into the urine and potentially a gradual decline in kidney function. Over time, the damage to the kidneys can become irreversible, increasing the risk of life-threatening complications, such as kidney failure, idiopathic nephrotic syndrome, blood clots and cardiovascular disease. Achieving complete remission is critical to help maintain kidney function and delay or prevent the onset of serious and potentially fatal complications.

About Roche in kidney and kidney-related diseases
For more than 20 years, we have combined innovation, scientific expertise and commitment to patients to address unmet needs in kidney diseases. Today, our industry-leading programme includes Gazyva®/Gazyvaro® (obinutuzumab), approved in the US and EU for adults with active lupus nephritis, and more than 10 phase II-III clinical studies in immune-mediated kidney and kidney-related diseases with some of the highest unmet needs.

Our aim is to continue delivering meaningful value for those affected, healthcare systems and society, and help address this growing public health burden.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Keri KC, et al.  Primary membranous nephropathy: comprehensive review and historical perspective. Postgrad Med L. 2019 Jan;95(1119). doi: 10.1136/postgradmedj-2018-135729.
[2] Kanigicherla DAK, et al. Long-term outcomes of persistent disease and relapse in primary membranous nephropathy. Nephrol Dial Transplant. 2016 Dec:31(12):2108-2114. doi: 10.1093/ndt/gfv435. Epub 2016 Jan 13.
[3] Furie RA, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022 Jan;81(1):100-07.
[4] Furie RA, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025 Feb;392:1471-83.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Roche Investor Relations

Investor Relations North America

Attachment

• Media & Investor Release Gazyva MAJESTY English

Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season




Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season

Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season

• First study showing that infants immunized against RSV in their first season had fewer RSV hospitalizations in their second season
• The study also showed a reduction of 85.9% in RSV-related lower respiratory tract infection hospitalizations in the first season

Data published in The Lancet Infectious Diseases and to be presented at RSVVW ’26 conference in Rome

Paris, February 16, 2026. A universal respiratory syncytial virus (RSV) immunization program using Beyfortus (nirsevimab) was associated with a statistically significant reduction in RSV-related hospitalizations in the second RSV season among infants immunized during their first season, according to a new study published in The Lancet Infectious Diseases. The NIRSE-GAL study, conducted in Galicia, Spain, is the first prospective real-world population study to evaluate the impact of a universal Beyfortus immunization program during two consecutive RSV seasons. The study findings, comparing the number of hospitalizations in immunized infants during their second RSV season versus the number of expected hospitalization cases based on data from recent seasons, are being presented at RSVVW ’26 (Respiratory Syncytial Virus Vaccines for the Word) conference in Rome, Italy.

The coverage rate was 94.4% among the cohort (11,796 infants out of 12,492 eligible) and the study showed a substantial reduction of 85.9% (95% confidence interval [CI] 80.2–90.0) in RSV-related lower respiratory tract infection (LRTI) hospitalizations during the first season. The study also showed 55.3% (95% CI 22.5-74.3) fewer hospitalizations in the second RSV season among infants who received a dose of Beyfortus during infancy. By preventing severe RSV infections during the first months of life, a critical period of lung development, it is thought the infants may be less prone to subsequent admissions from either RSV or other infections.

“This universal RSV immunization program with Beyfortus showed decreased RSV-related hospitalizations and outpatient illness burden during the first season, with persistent impact seen on RSV hospitalizations through the second season,” said Federico Martinón-Torres, Head of Pediatrics at Santiago University Hospital in Spain, and principal investigator of the NIRSE-GAL study. “These results offer compelling population-based data to inform infant immunization strategies and economic evaluation models.”

“This study builds upon our wealth of evidence supporting the public health value of a Beyfortus immunization program,” said Thomas Triomphe, Executive Vice President, Vaccines, Sanofi. “It’s exciting to see the significant impact of this infant immunization program during the first RSV season and truly remarkable to consider a benefit across two seasons.”

Further findings
The study also showed reductions in primary care consultations during the first RSV season, including:

• 30.8% (17.5-41.9) reduction in first consultations for acute bronchitis or bronchiolitis;
• 33.4% (21.6-43.4) reduction in consultations for lower respiratory tract infections and;
• 27.7% (14.9-38.5) reduction in consultations for wheezing or asthma.

Furthermore, rehospitalizations in infants previously hospitalized due to RSV decreased considerably during the second RSV season, with a 78.2% (25.6–93.6) reduction in RSV-related rehospitalizations and a 62.4% (30.9–79.6) reduction in LRTI rehospitalizations. These data support the hypothesis that early protection against RSV-related damage to the lungs may have lasting beneficial effects on respiratory health.

About RSV
RSV is a highly contagious virus that can lead to serious respiratory illness for infants. It is a leading cause of hospitalization in all infants, with most hospitalizations for RSV occurring in otherwise healthy infants born at term. Older infants born before the RSV season are also at risk of RSV disease and make up around half of infant RSV hospitalizations. Two out of three infants are infected with RSV during their first year of life and almost all children are infected by their second birthday. Globally, in 2019, there were approximately 33 million cases of RSV-associated acute lower respiratory infections leading to more than three million hospitalizations and an estimated 26,300 in-hospital RSV-attributable deaths of children younger than five years. RSV-related direct medical costs, globally — including hospital, outpatient, and follow-up care — were estimated at c.€5 billion in 2017.

About Beyfortus
Beyfortus (nirsevimab) is the first RSV immunization designed to help protect all infants through their first RSV season, including for those born healthy at term or preterm, and those with health conditions that make them vulnerable to RSV disease. Beyfortus is also approved for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

With an extended half-life of 71 days, Beyfortus is a long-acting monoclonal antibody for the prevention of RSV lower respiratory tract disease in infants.  Administration is timed to coincide with the RSV season and is provided directly to newborns and infants as a single dose. Beyfortus offers rapid protection without requiring activation of the immune system.

Along with efficacy and safety demonstrated in clinical studies, the effectiveness of Beyfortus has been evaluated in more than 50 real-world studies, including more than 400,000 infants who were immunized. Since the launch, over 11 million infants have been immunized with Beyfortus across more than 45 countries.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and creating compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | + 1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | + 33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | + 1 617 356 4751 | victor.rouault@sanofi.com
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com
Timothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com
Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com

Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com
Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Sanofi forward-looking statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group. 

Attachment

• Press_Release